September 5, 2017 06:29 AM EDT
Deals
Pharma

Em­bold­ened by re­cent R&D suc­cess­es, Mer­ck KGaA looks at sell­ing off $1B-plus con­sumer di­vi­sion

John Carroll

Editor & Founder

En­cour­aged by two no­table drug ap­provals af­ter a long Siber­ian win­ter of fail­ures and set­backs, Mer­ck KGaA has very pub­licly post­ed a ‘for sale …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Dai­ichi Sankyo taps new CEO, aims to build up ADC fran­chise

Ab­b­Vie ex­ec­u­tives bask in Skyrizi, Rin­voq suc­cess­es as the drugs take up Hu­mi­ra's man­tle

Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Roche sep­a­rates CFO, in­for­mat­ics posts; Lil­ly ex­ecs land at Kail­era, Neu­ro­crine

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times